絞り込み

16763

広告

Apixaban Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial.

著者 Avezum A , Lopes RD , Schulte PJ , Lanas F , Gersh BJ , Hanna M , Pais P , Erol C , Diaz R , Bahit MC , Bartunek J , De Caterina R , Goto S , Ruzyllo W , Zhu J , Granger CB , Alexander JH
Circulation.2015 Jun 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (254view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

-Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the ARISTOTLE trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves.
PMID: 26106009 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード